Pharmaceutical

The VPAS fallout continues – Celltrion pulls high-profi...

Jul 3, 2023

In late June 2023, Celltrion (South Korea) withdrew its key anti-cancer biosimil...

Camena bags $10m in funding from Mercia

Camena bags $10m in funding from Mercia

Jul 3, 2023

The bioscience company has received $10m Series A financing from asset manager M...

Baudax Bio acquires biotechnology firm TeraImmune

Baudax Bio acquires biotechnology firm TeraImmune

Jul 3, 2023

Baudax Bio has acquired all outstanding equity interests of biotechnology firm T...

Generative AI – beyond the hype

Generative AI – beyond the hype

Jul 3, 2023

2023 started with a buzz around ChatGPT, and more generally around the immense p...

Cyltezo Pen: first interchangeable biosimilar to Humira rolls out across US

Cyltezo Pen: first interchangeable biosimilar to Humira...

Jul 3, 2023

The Humira biosimilar from Boehringer Ingelheim launches amidst a loss of exclus...

Eli Lilly’s retatrutide sets new record for weight loss in obesity space

Eli Lilly’s retatrutide sets new record for weight loss...

Jul 3, 2023

Pipeline developments within the obesity space have recently garnered interest f...

Chinese NMPA approves Innovent and IASO Bio’s myeloma therapy

Chinese NMPA approves Innovent and IASO Bio’s myeloma t...

Jul 3, 2023

China has granted approval for Innovent Biologics and IASO Bio Fucaso for treati...

Madrigal seeks expedited approval for NASH treatment

Madrigal seeks expedited approval for NASH treatment

Jul 3, 2023

Madrigal Pharmaceuticals has commenced a rolling submission of an NDA seeking ex...

STAT+: Medical leaders decry Supreme Court decision on affirmative action

STAT+: Medical leaders decry Supreme Court decision on ...

Jul 2, 2023

Medical leaders reacted swiftly to the Supreme Court’s decision on affirmative a...

STAT+: Supreme Court strikes down use of affirmative action, a blow to efforts to diversify medical schools

STAT+: Supreme Court strikes down use of affirmative ac...

Jul 2, 2023

The U.S. Supreme Court struck down the use of affirmative action, ruling that it...

Eculizumab biosimilar by Turgut Ilaclari for Neuromyeli...

Jul 1, 2023

Eculizumab biosimilaris under clinical development by Turgut Ilaclari and curren...

(Glucagon + insulin human) by Abvance Therapeutics for ...

Jul 1, 2023

(Glucagon + insulin human)is under clinical development by Abvance Therapeutics ...

KP-910 by Kaken Pharmaceutical for Peripheral Neuropath...

Jul 1, 2023

KP-910is under clinical development by Kaken Pharmaceutical and currently in Pha...

[177Lu]Lu-rhPSMA-10.1 by Blue Earth Therapeutics for Me...

Jul 1, 2023

[177Lu]Lu-rhPSMA-10.1is under clinical development by Blue Earth Therapeutics an...

ABBV-444 by AbbVie for Keratoconjunctivitis Sicca (Dry ...

Jul 1, 2023

ABBV-444is under clinical development by AbbVie and currently in Phase III for K...

XKDCT-080 by Guangdong Xiankangda Biotechnology for Col...

Jul 1, 2023

XKDCT-080is under clinical development by Guangdong Xiankangda Biotechnology and...